Medicenne Reports MDNA209 Preclinical Autoimmune Disease Findings
Medicenne reported CD122 blockade and extended survival with MDNA209 in preclinical models of autoimmune disease.
Medicenne reported CD122 blockade and extended survival with MDNA209 in preclinical models of autoimmune disease.